Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 27, Issue 3, 2011, Pages 665-676

  Bjerke, Maria ^a   Zetterberg, Henrik ^a   Edman, Åke ^a   Blennow, Kaj ^a   Wallin, Anders ^a   Andreasson, Ulf ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Alzheimer's disease; amyloid ; biomarkers; cerebrospinal fluid; matrix metalloproteinases; myelin basic protein; neurofilament light; tau; vascular dementia

Indexed keywords

ALBUMIN; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; FATTY ACID BINDING PROTEIN; GELATINASE A; GELATINASE B; HEART FATTY ACID BINDING PROTEIN; HYPERPHOSPHORYLATED TAU PROTEIN 181; INTERSTITIAL COLLAGENASE; METALLOPROTEINASE; MYELIN BASIC PROTEIN; NEUROFILAMENT PROTEIN; STROMELYSIN; STROMELYSIN 2; TAU PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HUMAN; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; WHITE MATTER;

EID: 82555184961     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-110566     Document Type: Article

References (81)

1. Erkinjuntti T, Ostbye T, Steenhuis R, Hachinski V (1997) The effect of different diagnostic criteria on the prevalence of dementia. N Engl J Med 337, 1667-1674. (Pubitemid 27510105)
2. Wallin A (1998) The overlap between Alzheimer's disease and vascular dementia: The role of white matter changes. Dement Geriatr Cogn Disord 9(Suppl 1), 30-35. (Pubitemid 28325640)
3. Wallin A, MilosV, Sjogren M, Pantoni L, Erkinjuntti T (2003) Classification and subtypes of vascular dementia. Int Psychogeriatr 15(Suppl 1), 27-37. (Pubitemid 37175164)
4. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387-403.
5. Blennow K (2004) Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 1, 213-225. (Pubitemid 46589353)
6. Petzold A, Keir G, Warren J, Fox N, Rossor MN (2007) A systematic review and meta-analysis of CSF neurofilament protein levels as biomarkers in dementia. Neurodegener Dis 4, 185-194. (Pubitemid 47000412)
7. Omlin FX, Webster HD, Palkovits CG, Cohen SR (1982) Immunocytochemical localization of basic protein in major dense line regions of central and peripheral myelin. J Cell Biol 95, 242-248. (Pubitemid 13197094)
8. Brouns R, De Vil B, Cras P, De Surgeloose D, Marien P, De Deyn PP (2010) Neurobiochemical markers of brain damage in cerebrospinal fluid of acute ischemic stroke patients. Clin Chem 56, 451-458.
9. Matsui Y, Satoh K, Mutsukura K, Watanabe T, Nishida N, Matsuda H, Sugino M, Shirabe S, Eguchi K, KataokaY(2010) Development of an ultra-rapid diagnostic method based on heart-type fatty acid binding protein levels in the CSF of CJD patients. Cell Mol Neurobiol 30, 991-999.
10. Rosenberg GA (2009) Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol 8, 205-216.
11. Yong VW, Power C, Forsyth P, Edwards DR (2001) Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2, 502-511. (Pubitemid 33676585)
12. Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S (2008) Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol 18, 240-252.
13. Barrett AJ, Starkey PM (1973) The interaction of alpha 2-macroglobulin with proteinases, Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism. Biochem J 133, 709-724.
14. Gardner J, Ghorpade A (2003) Tissue inhibitor of metalloproteinase (TIMP)-1: The TIMPed balance of matrix metalloproteinases in the central nervous system. J Neurosci Res 74, 801-806. (Pubitemid 37490412)
15. Lambert E, Boudot C, Kadri Z, Soula-Rothhut M, Sowa ML, Mayeux P, Hornebeck W, Haye B, Petitfrere E (2003) Tissue inhibitor of metalloproteinases-1 signalling pathway leading to erythroid cell survival. Biochem J 372, 767-774. (Pubitemid 36760390)
16. Chesler L, Golde DW, Bersch N, Johnson MD (1995) Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1. Blood 86, 4506-4515.
17. Rosenberg GA, Estrada EY, Dencoff JE (1998) Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 29, 2189-2195. (Pubitemid 28443538)
18. Asahi M, Asahi K, Jung JC, del Zoppo GJ, Fini ME, Lo EH (2000) Role for matrix metalloproteinase 9 after focal cerebral ischemia: Effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 20, 1681-1689.
19. Gu Z, Cui J, Brown S, Fridman R, Mobashery S, Strongin AY, Lipton SA (2005) A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci 25, 6401-6408. (Pubitemid 40962536)
20. Rosell A, Lo EH (2008) Multiphasic roles for matrix metalloproteinases after stroke. Curr Opin Pharmacol 8, 82-89.
21. Lee SR, Kim HY, Rogowska J, Zhao BQ, Bhide P, Parent JM, Lo EH (2006) Involvement of matrix metalloproteinase in neuroblast cell migration from the subventricular zone after stroke. J Neurosci 26, 3491-3495.
22. Zhao BQ,Wang S,KimHY, Storrie H, Rosen BR, Mooney DJ, Wang X, Lo EH (2006) Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med 12, 441-445.
23. Adair JC, Charlie J, Dencoff JE, Kaye JA, Quinn JF, Camicioli RM, Stetler-Stevenson WG, Rosenberg GA (2004) Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease. Stroke 35, e159-e162.
24. Deb S, Gottschall PE (1996) Increased production of matrix metalloproteinases in enriched astrocyte and mixed hippocampal cultures treated with beta-amyloid peptides. J Neurochem 66, 1641-1647. (Pubitemid 26090566)
25. Mizoguchi H, Takuma K, Fukuzaki E, Ibi D, Someya E, Akazawa KH, Alkam T, Tsunekawa H, Mouri A, Noda Y, Nabeshima T, Yamada K (2009) Matrix metalloprotease-9 inhibition improves amyloid beta-mediated cognitive impairment and neurotoxicity in mice. J Pharmacol Exp Ther 331, 14-22.
26. Reitz C, van Rooij FJ, Soares HD, de Maat MP, Hofman A, Witteman JC, Breteler MM (2010) Matrix metalloproteinase 3 haplotypes and plasma amyloid beta levels: The Rotterdam Study. Neurobiol Aging 31, 715-718.
27. Talamagas AA, Efthimiopoulos S, Tsilibary EC, Figueiredo- Pereira ME, TziniaAK(2007) Abeta(1-40)-induced secretion of matrix metalloproteinase-9 results in sAPPalpha release by association with cell surface APP. Neurobiol Dis 28, 304-315. (Pubitemid 350123595)
28. Backstrom JR, Lim GP, Cullen MJ, Tokes ZA (1996) Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloidbeta peptide. J Neurosci 16, 7910-7919. (Pubitemid 26405054)
29. Yan P, Hu X, Song H, Yin K, Bateman RJ, Cirrito JR, Xiao Q, Hsu FF,TurkJW,Xu J, HsuCY, HoltzmanDM,LeeJM(2006) Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J Biol Chem 281, 24566-24574. (Pubitemid 44274231)
30. Mlekusch R, Humpel C (2009) Matrix metalloproteinases- 2 and -3 are reduced in cerebrospinal fluid with low betaamyloid1- 42 levels. Neurosci Lett 466, 135-138.
31. American Psychiatric Association, APA (1987) Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association, Washington, D.C.
32. World Health Organization WHO (1992) The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines,World Health Organization, Geneva, Switzerland.
33. Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, Roman GC, Chui H, Desmond DW (2000) Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl 59, 23-30. (Pubitemid 30479402)
34. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E (1995) Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 26, 231-245. (Pubitemid 26002016)
35. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjogren M, Andreasen N, Blennow K (2000) Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: A sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 285, 49-52. (Pubitemid 30224621)
36. Vanderstichele KB, D'Heuvaert N, Buyse M, Wallin A, Andreasen N, Seubert P, Van De Vorde A, Vanmechelen E (1998) Development of a specific diagnostic test for measurement ofβ-amyloid (1-42) in CSF. In Progress in Alzheimer's and Parkinson's Diseases, Fisher A, Hanin I, Yoshinda M, eds., Plenum Press, New York, pp. 773-778.
37. Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, Minthon L, Wallin A, Blennow K, Vanmechelen E (2000) Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid 7, 245-258.
38. Norgren N, Rosengren L, Stigbrand T (2003) Elevated neurofilament levels in neurological diseases. Brain Res 987, 25-31. (Pubitemid 37267883)
39. Wodzig KW, Pelsers MM, van der Vusse GJ, Roos W, Glatz JF (1997) One-step enzyme-linked immunosorbent assay (ELISA) for plasma fatty acid-binding protein. Ann Clin Biochem 34(Pt 3), 263-268. (Pubitemid 27236929)
40. Tibbling G, Link H, Ohman S (1977) Principles of albumin and IgG analyses in neurological disorders, I Establishment of reference values. Scand J Clin Lab Invest 37, 385-390. (Pubitemid 8387871)
41. Eriksson L, K-WN JE, Trygg J, Wikström C, Wold S (2006) Multi- and Megavariate Data Analysis Part II: Advanced Applications and Method Extensions Umetrics AB, Umeå.
42. Pantoni L (2002) Pathophysiology of age-related cerebral white matter changes. Cerebrovasc Dis 13(Suppl 2), 7-10. (Pubitemid 34233902)
43. Ogata J (1999) Vascular dementia: The role of changes in the vessels. Alzheimer Dis Assoc Disord 13(Suppl 3), S55-S58.
44. Kokmen E, Whisnant JP, O'Fallon WM, Chu CP, Beard CM (1996) Dementia after ischemic stroke: A population-based study in Rochester, Minnesota (1960-1984). Neurology 46, 154-159. (Pubitemid 26156122)
45. Friede RL, Samorajski T (1970) Axon caliber related to neurofilaments and microtubules in sciatic nerve fibers of rats and mice. Anat Rec 167, 379-387.
46. Sjogren M, Blomberg M, Jonsson M, Wahlund LO, Edman A, Lind K, Rosengren L, Blennow K, Wallin A (2001) Neurofilament protein in cerebrospinal fluid: A marker of white matter changes. J Neurosci Res 66, 510-516. (Pubitemid 33027419)
47. Bjerke M, Andreasson U, Rolstad S, Nordlund A, Lind K, Zetterberg H, Edman A, Blennow K, Wallin A (2009) Subcortical vascular dementia biomarker pattern in mild cognitive impairment. Dement Geriatr Cogn Disord 28, 348-356.
48. Sjogren M, Davidsson P, Tullberg M, Minthon L, Wallin A, Wikkelso C, Granerus AK, Vanderstichele H, Vanmechelen E, Blennow K (2001) Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry 70, 624-630. (Pubitemid 32397998)
49. Lim ET, Sellebjerg F, Jensen CV, Altmann DR, Grant D, Keir G, Thompson EJ, Giovannoni G (2005) Acute axonal damage predicts clinical outcome in patients with multiple sclerosis. Mult Scler 11, 532-536. (Pubitemid 41387697)
50. Rockwood K, Macknight C,Wentzel C, Black S, Bouchard R, Gauthier S, Feldman H, Hogan D, Kertesz A, Montgomery P (2000) The diagnosis of 'mixed' dementia in the Consortium for the Investigation of Vascular Impairment of Cognition (CIVIC). Ann N Y Acad Sci 903, 522-528. (Pubitemid 30251598)
51. Wallin A, Gottfries CG, Karlsson I, Svennerholm L (1989) Decreased myelin lipids in Alzheimer's disease and vascular dementia. Acta Neurol Scand 80, 319-323. (Pubitemid 19264763)
52. Ihara M, Polvikoski TM, Hall R, Slade JY, Perry RH, Oakley AE, Englund' E, O'Brien JT, Ince PG, Kalaria RN (2010) Quantification of myelin loss in frontal lobe white matter in vascular dementia, Alzheimer's disease, and dementia with Lewy bodies. Acta Neuropathol 119, 579-589.
53. Chiasserini D, Parnetti L, Andreasson U, Zetterberg H, Giannandrea D, Calabresi P, BlennowK(2010) CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease. J Alzheimers Dis 22, 1281-1288.
54. Nagga K, Gottfries J, Blennow K, Marcusson J (2002) Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer's disease and vascular dementia. Dement Geriatr Cogn Disord 14, 183-190. (Pubitemid 36151485)
55. Gouw AA, Seewann A, van der Flier WM, Barkhof F, Rozemuller AM, Scheltens P, Geurts JJ (2011) Heterogeneity of small vessel disease: A systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry 82, 126-135.
56. Buee L, Hof PR, Bouras C, Delacourte A, Perl DP, Morrison JH, Fillit HM (1994) Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders. Acta Neuropathol 87, 469-480. (Pubitemid 24128974)
57. Zhang X, Zhou K,Wang R, Cui J, Lipton SA, Liao FF, Xu H, and ZhangYW(2007) Hypoxia-inducible factor 1alpha (HIF- 1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation. J Biol Chem 282, 10873-10880. (Pubitemid 47100783)
58. Murphy G, Nagase H (2008) Progress in matrix metalloproteinase research. Mol Aspects Med 29, 290-308.
59. Candelario-Jalil E, Yang Y, Rosenberg GA (2009) Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience 158, 983-994.
60. Clark AW, Krekoski CA, Bou SS, Chapman KR, Edwards DR (1997) Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett 238, 53-56. (Pubitemid 28015782)
61. Lee SR, Tsuji K, Lo EH (2004) Role of matrix metalloproteinases in delayed neuronal damage after transient global cerebral ischemia. J Neurosci 24, 671-678. (Pubitemid 38166493)
62. Fujimoto M, Takagi Y, Aoki T, Hayase M, Marumo T, Gomi M, Nishimura M, Kataoka H, Hashimoto N, Nozaki K (2008) Tissue inhibitor of metalloproteinases protect blood-brain barrier disruption in focal cerebral ischemia. J Cereb Blood Flow Metab 28, 1674-1685.
63. Cuadrado E, Rosell A, Penalba A, Slevin M, Alvarez-Sabin J, Ortega-Aznar A, Montaner J (2009) Vascular MMP-9/TIMP- 2 and neuronal MMP-10 up-regulation in human brain after stroke: A combined laser microdissection and protein array study. J Proteome Res 8, 3191-3197.
64. Choi DH, Kim EM, Son HJ, Joh TH, Kim YS, Kim D, Flint Beal M, Hwang O (2008) A novel intracellular role of matrix metalloproteinase-3 during apoptosis of dopaminergic cells. J Neurochem 106, 405-415. (Pubitemid 351840221)
65. YoshiyamaY, Asahina M, Hattori T (2000) Selective distribution of matrix metalloproteinase-3 (MMP-3) in Alzheimer's disease brain. Acta Neuropathol 99, 91-95. (Pubitemid 30093413)
66. Asahina M, Yoshiyama Y, Hattori T (2001) Expression of matrix metalloproteinase-9 and urinary-type plasminogen activator in Alzheimer's disease brain. Clin Neuropathol 20, 60-63. (Pubitemid 32234485)
67. Vargas T, Ugalde C, Spuch C, Antequera D, Moran MJ, Martin MA, Ferrer I, Bermejo-Pareja F, Carro E (2010) Abeta accumulation in choroid plexus is associated with mitochondrial-induced apoptosis. Neurobiol Aging 31, 1569-1581.
68. Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G (1997) Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 17, 2653-2657. (Pubitemid 27154998)
69. Aliyev A, Seyidova D, Rzayev N, Obrenovich ME, Lamb BT, Chen SG, Smith MA, Perry G, de la Torre JC, Aliev G (2004) Is nitric oxide a key target in the pathogenesis of brain lesions during the development of Alzheimer's disease? Neurol Res 26, 547-553. (Pubitemid 38879237)
70. Keil U, Bonert A, Marques CA, Scherping I, Weyermann J, Strosznajder JB, Muller-Spahn F, Haass C, Czech C, Pradier L, Muller WE, EckertA(2004) Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis. J Biol Chem 279, 50310-50320. (Pubitemid 39577847)
71. Canevari L, Clark JB, Bates TE (1999) beta-Amyloid fragment 25-35 selectively decreases complex IV activity in isolated mitochondria. FEBS Lett 457, 131-134. (Pubitemid 29387424)
72. Casley CS, Canevari L, Land JM, Clark JB, SharpeMA(2002) Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities. J Neurochem 80, 91-100. (Pubitemid 34614581)
73. Marques CA, Keil U, Bonert A, Steiner B, Haass C, Muller WE, Eckert A (2003) Neurotoxic mechanisms caused by the Alzheimer's disease-linked Swedish amyloid precursor protein mutation: Oxidative stress, caspases, and the JNK pathway. J Biol Chem 278, 28294-28302. (Pubitemid 36900031)
74. Takuma K,Yao J, Huang J,XuH, Chen X, Luddy J,TrillatAC, Stern DM, Arancio O,Yan SS (2005)ABADenhances Abetainduced cell stress via mitochondrial dysfunction. FASEB J 19, 597-598. (Pubitemid 40471256)
75. Zhu Y, Hoell P, Ahlemeyer B, Krieglstein J (2006) PTEN: A crucial mediator of mitochondria-dependent apoptosis. Apoptosis 11, 197-207. (Pubitemid 43291020)
76. Lee JM, Yin KJ, Hsin I, Chen S, Fryer JD, Holtzman DM, Hsu CY, Xu J (2003) Matrix metalloproteinase-9 and spontaneous hemorrhage in an animal model of cerebral amyloid angiopathy. Ann Neurol 54, 379-382. (Pubitemid 37072041)
77. Harkness KA, Adamson P, Sussman JD, Davies-Jones GA, Greenwood J, Woodroofe MN (2000) Dexamethasone regulation of matrix metalloproteinase expression inCNSvascular endothelium. Brain 123(Pt 4), 698-709. (Pubitemid 30162719)
78. Mori T, Wang X, Aoki T, Lo EH (2002) Downregulation of matrix metalloproteinase-9 and attenuation of edema via inhibition of ERK mitogen activated protein kinase in traumatic brain injury. J Neurotrauma 19, 1411-1419. (Pubitemid 35403670)
79. Hernandez-Guillamon M, Delgado P, Ortega L, Pares M, Rosell A, Garcia-Bonilla L, Fernandez-Cadenas I, Borrell-Pages M, Boada M, Montaner J (2009) Neuronal TIMP-1 release accompanies astrocytic MMP-9 secretion and enhances astrocyte proliferation induced by beta-amyloid 25- 35 fragment. J Neurosci Res 87, 2115-2125.
80. Lorenzl S, Albers DS, LeWitt PA, Chirichigno JW, Hilgenberg SL, Cudkowicz ME, BealMF(2003) Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases. J Neurol Sci 207, 71-76. (Pubitemid 36292132)
81. Stomrud E, Bjorkqvist M, Janciauskiene S, Minthon L, Hansson O (2010) Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease. Alzheimers Res Ther 2, 20.